Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV.
暂无分享,去创建一个
C. Cannon | D. McGuire | R. Pratley | B. Charbonnel | S. Dagogo-Jack | F. Cosentino | R. Frederich | Jie Liu | A. Pong | D. Cherney | M. Maldonado | Chih-Chin Liu
[1] C. Cannon,et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.
[2] C. Cannon,et al. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease , 2020, Circulation.
[3] C. Cannon,et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.
[4] A. Levin,et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.
[5] D. Wheeler,et al. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.